Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling

Published: Tuesday, July 09, 2013
Last Updated: Tuesday, July 09, 2013
Bookmark and Share
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.

To this end, Evotec will perform quantitative chemical proteomics services (Cellular Target Profiling) to de-convolute phenotypic screening results obtained by Dow.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We look forward to working with Dow AgroSciences on this project. This collaboration highlights the broad applicability of Evotec‘s industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context.”

Dr William Kleschick, Discovery Global Leader of Dow AgroSciences, added: “Dow AgroSciences is pleased to announce this new partnership with Evotec, an innovative leader in advanced chemical proteomics. This collaboration enhances Discovery’s technology tool-box to accelerate our efforts to deliver novel solutions to our customers around the world.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec and IR Pharma Establish Drug Discovery Alliance
Companies have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.
Thursday, February 16, 2012
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
Evotec to apply integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Wednesday, November 24, 2010
Evotec and APEIRON Biologics build Pain Alliance
The collaboration will initially identify small molecule modulators of DREAM - Downstream Regulatory Element Antagonistic Modulator.
Monday, November 01, 2010
Evotec Licenses Phase II Insomnia Candidate to Jingxin Pharma for Development in China
Jingxin Pharma will initiate clinical trials with EVT 201 in China in 2011.
Monday, November 01, 2010
Evotec Completes Acquisition of DeveloGen
The transaction adds two complementary alliances - one with Boehringer Ingelheim and one with Andromeda to Evotec's portfolio of core assets.
Friday, September 03, 2010
Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim
The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.
Thursday, June 17, 2010
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
Evotec receives EUR 2.0M milestone payment with initiation of the Phase I clinical studies for the compound.
Thursday, May 20, 2010
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!